Mechanism of Action (MOA)

IPF pathogenesis and nintedanib mechanism of action

Nintedanib mechanism of action

Nintedanib is a tyrosine kinase inhibitor1

Nintedanib inhibitorimage

Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling. In addition, nintedanib inhibits Flt-3 (Fms-like tyrosine protein kinase), Lck (lymphocyte-specific tyrosine-protein kinase), Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases.1


  1. CYENDIV® India pack insert version dated 10th August 2018.
  2. Hilberg F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774–4782.
  3. Wollin L., et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209–220.
  4. Wollin L., et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434–1445.